Live
CellComplete biosynthesis of nicotineFierceBiotechCancer screening costs rival diagnosis fears as patients fall behindFierceBiotechEpia Neuro launches with BCI device to help stroke patients rework brain signalsEndpoints NewsNovo and Lilly battle over GLP-1 claims only a head-to-head trial can answerEndpoints NewsDrug substance maker raises prices due to energy crisis; SpectronRX gets $85MEndpoints NewsLipocine's postpartum depression drug fails; AstraZeneca claims liver cancer winEndpoints NewsTrump is preparing 100% tariffs on some drugmakers, documents showBioWorldHoliday noticeEndpoints NewsClaim of ChatGPT treating Rosie the dog's cancer stirs AI biotech debateIlluminaIllumina (NASDAQ: ILMN) nominates David P. King as three directors retire - Stock TitanIlluminaThree Illumina directors are leaving as the company puts David King on its board slate - Stock TitanIlluminaIllumina Announces Changes to Board of Directors - PR Newswire
Endpoints News Apr 2, 2026

Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer

Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer

Original
Body unavailable. Use the original source.

Directory

59 All